A chemicals perspective on designing with sustainable plastics OECDOECD Environment
With global plastic production soaring over the last 50 years, it is more urgent than ever to continue developing sustainable plastic products from a chemicals perspective. Our new report “A Chemicals Perspective on Designing with Sustainable Plastics - Goals, Considerations and Trade-offs” and its four supporting case studies (biscuit wrappers, detergent bottles, flooring and insulation) look at the plastic material selection process from a chemicals perspective to enable the creation of inherently sustainable plastic products.
Developed with country delegates, designers, industry stakeholders and NGOs, it will help designers and engineers select sustainable plastic for their products by equipping them with the right knowledge of chemicals.
A webinar to discuss the key findings of the reports took place on 7 December. Watch the video replay below to hear perspectives from countries and industry on the value of the initiative.
Presentation of the EFSA's second scientific conference, held on 14-16 October 2015 in Milan, Italy.
DRIVERS FOR EMERGING ISSUES IN ANIMAL AND PLANT HEALTH
A chemicals perspective on designing with sustainable plastics OECDOECD Environment
With global plastic production soaring over the last 50 years, it is more urgent than ever to continue developing sustainable plastic products from a chemicals perspective. Our new report “A Chemicals Perspective on Designing with Sustainable Plastics - Goals, Considerations and Trade-offs” and its four supporting case studies (biscuit wrappers, detergent bottles, flooring and insulation) look at the plastic material selection process from a chemicals perspective to enable the creation of inherently sustainable plastic products.
Developed with country delegates, designers, industry stakeholders and NGOs, it will help designers and engineers select sustainable plastic for their products by equipping them with the right knowledge of chemicals.
A webinar to discuss the key findings of the reports took place on 7 December. Watch the video replay below to hear perspectives from countries and industry on the value of the initiative.
Presentation of the EFSA's second scientific conference, held on 14-16 October 2015 in Milan, Italy.
DRIVERS FOR EMERGING ISSUES IN ANIMAL AND PLANT HEALTH
PANEL 5: Substances of concern (SVHCs) in products – whose job is it to control these in a free trade world? - Karin Kilian, Policy Officer, EU-Commission
DEBATE: Can product stewardship replace regulation? Case nanomaterials
Presentation: David Warheit, Technical Fellow − Toxicology and Risk Assessment, The Chemours Company, US
PANEL 4: Speeding up chemical assessments: from novel information to new management approaches, what works? - Erika Kunz, Head of Global Registration and Evaluation of Chemicals, Clariant, Germany
Post-Market Surveillance Activities to Ensure the Safe Use of Medical DevicesUN SPHS
By Mr. Bader E. ALoufi, Head, Post-Market Clinical Evaluation, Medical Devices Sector, Saudi Food and Drug Authority (SFDA), delivered at the Global Forum 2020 Medical Devices and Safety session.
Call for articles, special issue on: "The Future of Ecolabels"Fabio Iraldo
The German Environment Agency (UBA), the Oeko-Institute, adelphi consult GmbH and the Institute for Research on Energy and Environmental Economics and Policy (IEFE) of Bocconi University are promoting and launching the present call for contributions. The call aims to identify and describe the key challenges facing ecolabels, such as defining criteria to deal with critical raw materials, chain-of-custody and traceability of raw material value chains, integration of social criteria and human rights aspects in ecolabels, addressing issues of product durability and obsolescence and implementing a harmonized performance and impact measurement system for ecolabels.
Open Source Pharma: Game changing for innovative medicineOpen Source Pharma
Presentation given by Dimitrios Tzalis, of the European Lead Factory, at the Open Source Pharma Conference at Rockefeller Foundation Bellagio Center, July 2014.
Dimitrios Tzalis Bio:
http://www.opensourcepharma.net/participants/dimitrios-tzalis
Conference Agenda (See Day 1, Session 2):
http://www.opensourcepharma.net/agenda.html
PANEL 5: Substances of concern (SVHCs) in products – whose job is it to control these in a free trade world? - Ravi Agarval, Director, Toxics Link, India
Presented by Tomasz Sablinski at the Open Source Pharma Conference in July 2014 at Rockefeller Foundation Bellagio Center.
Tomasz Sablinski's bio: http://www.opensourcepharma.net/participants/tomasz-sablinski
Conference agenda: http://www.opensourcepharma.net/agenda.html
Open Source Pharma: OSDD: An innovative model for distributed co-creationOpen Source Pharma
Presentation given by Samir Brahmachari about the open research model used by Open Source Drug Discovery. The talk was given at the Open Source Pharma Conference at Rockefeller Foundation Bellagio Center in July 2014.
Samir Brahmachari Bio:
http://www.opensourcepharma.net/participants/samir-brahmachari
Conference Agenda (see Day 1, Session 4):
http://www.opensourcepharma.net/agenda.html
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...MilliporeSigma
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
PANEL 5: Substances of concern (SVHCs) in products – whose job is it to control these in a free trade world? - Karin Kilian, Policy Officer, EU-Commission
DEBATE: Can product stewardship replace regulation? Case nanomaterials
Presentation: David Warheit, Technical Fellow − Toxicology and Risk Assessment, The Chemours Company, US
PANEL 4: Speeding up chemical assessments: from novel information to new management approaches, what works? - Erika Kunz, Head of Global Registration and Evaluation of Chemicals, Clariant, Germany
Post-Market Surveillance Activities to Ensure the Safe Use of Medical DevicesUN SPHS
By Mr. Bader E. ALoufi, Head, Post-Market Clinical Evaluation, Medical Devices Sector, Saudi Food and Drug Authority (SFDA), delivered at the Global Forum 2020 Medical Devices and Safety session.
Call for articles, special issue on: "The Future of Ecolabels"Fabio Iraldo
The German Environment Agency (UBA), the Oeko-Institute, adelphi consult GmbH and the Institute for Research on Energy and Environmental Economics and Policy (IEFE) of Bocconi University are promoting and launching the present call for contributions. The call aims to identify and describe the key challenges facing ecolabels, such as defining criteria to deal with critical raw materials, chain-of-custody and traceability of raw material value chains, integration of social criteria and human rights aspects in ecolabels, addressing issues of product durability and obsolescence and implementing a harmonized performance and impact measurement system for ecolabels.
Open Source Pharma: Game changing for innovative medicineOpen Source Pharma
Presentation given by Dimitrios Tzalis, of the European Lead Factory, at the Open Source Pharma Conference at Rockefeller Foundation Bellagio Center, July 2014.
Dimitrios Tzalis Bio:
http://www.opensourcepharma.net/participants/dimitrios-tzalis
Conference Agenda (See Day 1, Session 2):
http://www.opensourcepharma.net/agenda.html
PANEL 5: Substances of concern (SVHCs) in products – whose job is it to control these in a free trade world? - Ravi Agarval, Director, Toxics Link, India
Presented by Tomasz Sablinski at the Open Source Pharma Conference in July 2014 at Rockefeller Foundation Bellagio Center.
Tomasz Sablinski's bio: http://www.opensourcepharma.net/participants/tomasz-sablinski
Conference agenda: http://www.opensourcepharma.net/agenda.html
Open Source Pharma: OSDD: An innovative model for distributed co-creationOpen Source Pharma
Presentation given by Samir Brahmachari about the open research model used by Open Source Drug Discovery. The talk was given at the Open Source Pharma Conference at Rockefeller Foundation Bellagio Center in July 2014.
Samir Brahmachari Bio:
http://www.opensourcepharma.net/participants/samir-brahmachari
Conference Agenda (see Day 1, Session 4):
http://www.opensourcepharma.net/agenda.html
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...MilliporeSigma
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...Merck Life Sciences
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...Merck Life Sciences
Biopharmaceutical manufacturing capacities have expanded dramatically which has resulted in an increased demand for single-use systems (SUS) as they have their own advantages. Although SUS are well established in the biopharmaceutical industry there is limited guidance on regulatory expectations. Please attend the webinar to learn more!
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...MilliporeSigma
Biopharmaceutical manufacturing capacities have expanded dramatically which has resulted in an increased demand for single-use systems (SUS) as they have their own advantages. Although SUS are well established in the biopharmaceutical industry there is limited guidance on regulatory expectations. Please attend the webinar to learn more!
R3-Nordic, the Nordic Society of Cleanroom Technology, is a non-profit, independent association for the promotion of new technologies in cleanroom technology and contamination control in the Nordic countries. The aim of the annual R3Nordic Symposium is to provide knowledge within the pharmaceutical, food and electronic industries as well as hospitals and hospital pharmacies. This year the sessions at the 45th R3Nordic Symposium are Pharma, Hospital and General Sessions and the presentations deal with construction and design, planning, auditing, contamination control, cleanroom technology and management, sterilization techniques, cleaning of clean rooms, protective clothing, monitoring techniques, rapid test methods and regulations in clean and controlled rooms. The venue of the annual symposium 2014 is Naantali Spa in Naantali. The persons involved in the Programme Committee are Satu Salo, Kari Leonsaari, Leila Kakko, Sirkka Malmioja, Antti Mikkola, Raimo Pärssinen and Gun Wirtanen. The editors of the proceedings would like to express their gratitude to the speakers for preparing the abstracts published in the journal Renhetsteknik 1/14 as well as the extended abstracts or full papers published in these electronic proceedings.
Emerging research agenda in pesticide scienceDevakumar Jain
I request the users to cite the source while using any material from this presentation. Once this slide deck is used in my publication, it can be freely used.
Watch the presentation of this webinar here: https://bit.ly/3tDy8Ei
Recent PDA/BioPhorum publications outline risks for PUPSIT in sterilizing filtration. This webinar will summarize the key points and best practices for implementing PUPSIT.
PDA and BioPhorum have partnered to form a task force whose goal was to provide the industry and regulators with scientific data and analysis on the potential risks and benefits of implementing PUPSIT to improve sterility assurance. This webinar will describe the data generated by the task force studies and discuss considerations and best practices when implementing PUPSIT.
In this webinar, you will learn:
• How changing industry perspectives help overcome regulatory concerns and may influence regulatory perspective
• How improved process understanding affects risk assessment
• How improved final fill assembly design simplifies PUPSIT
Aseptic Process Sampling to address Risk of Contamination & Containment in co...Merck Life Sciences
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
Aseptic Process Sampling to address Risk of Contamination & Containment in co...MilliporeSigma
Watch this webinar here: bit.ly/asepticwebinar2020
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
Antimicrobial Resistance (AMR) in the UK & Germany: Synergies, Opportunities ...KTN
The webinar presented the findings of the output report and gave delegates the opportunity to talk directly with representatives who went on the Mission in a Q&A Session. KTN hosted this event on behalf of Innovate UK and was presented by Sandeep Sandhu, KTN, Peter Dirken, Innovate UK, Phil Packer, Innovate UK, Daniel Hynes, Destiny Pharma, Till Bachman, University of Edinburgh, Gabriela Juarez Martinez, KTN, Mireille Owen-Hughes, EEN.
To help UK businesses become truly global enterprises through strategic collaboration, Innovate UK launched its Global Expert Missions in October 2017. Delivered by KTN, the missions provide an expert-led evidence base to strengthen Innovate UK’s global investment strategy: how and where it should invest to create UK business opportunities in partnerships with key economies.
Find out more here: https://ktn-uk.co.uk/news/antimicrobial-resistance-amr-in-germany-global-expert-mission-dissemination-webinar-recording-and-slides-now-available/
Let's work towards a #SaferWorldbyDesign - Knowledge-integrated Toxicology an...Barry Hardy
Let's work towards a #SaferWorldbyDesign - Knowledge-integrated Toxicology and Safety Assessment, Barry Hardy, OpenTox Asia 2019, Hyderabad, India. To make a good decision we need to bring both expertise and relevant information together to form the basis for a structured well-informed discussion leading to best judgement based on available evidence and opinions formed on it. Such a knowledge integration is required in many areas of toxicology and safety assessment based on scientific knowledge generated by a growing number of alternative testing research methods and initiatives. Integration may include evidence from in vitro or in silico methods, biology or chemistry, science and engineering, human health or environment-oriented, and requires both effective organisation of knowledge and communications to reach common understandings.
The requirements, context and format for applications may vary e.g., asking and answering scientific questions, carrying out a risk assessment on products, or performing a regulatory decision or submission. All applications however require a sound reproducible scientific basis and the use of good practices in characterising experiments, organising data and describing concepts in our ontology and knowledge framework.
There is a growing opportunity to develop knowledge integration based on combining emerging concepts and frameworks e.g., OpenTox for data integration and resource interoperability, adverse outcome pathways for mapping data to events, evidence-based methods including systematic review applied to weight of evidence and read across methods for combining evidence from chemical or biological mechanistic categories.
We also need community frameworks to bring different disciplines together for fruitful interactions and discussions.
In this seminar we will review recent developments related to integrated testing and assessment including applications to chemicals, cosmetic ingredients and nanotechnology and including 3Rs goals of reducing and replacing animal testing.
SMi proudly presents due to the huge success of our Pharmaceutical Microbiology UK event the launch of SMi's Pharmaceutical Microbiology USA Conference in San Diego on 8th and 9th June 2017. Latest reports show that global rapid microbiology tests market to reach a net worth USD 19.5 Bn by 2022.* With the field growing at such a rapid rate SMi would like to take this opportunity to invite you to join us as we address the hot topics of the industry such as RMM, low endotoxin recovery, risk assessment and many more! With the forthcoming changes to annexe 1, take this opportunity to hear direct regulatory feedback and benchmark your strategies amongst industry peers. Our 2 day event will include presentations from both regulatory and industry experts sharing recent case studies and developing trends in the field of pharmaceutical microbiology
The SMART-NANO project has enabled the development of an innovative and cost-effective technology platform that provides a complete "sample-to-result" solution for the detection, identification and measurement of nanoparticles designed in a wide range of matrices.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
1. Virtual update for AMiCI contacts
Francy Crijns (Chair) – Minna Keinänen-Toivola (Vice-Chair)
1st February 2018
AntiMicrobial
Coating Innovations
2. • Chair of the Action
Dr. Francy Crijns
Zuyd University of Applied Sciences, NL
francy.crijns@zuyd.nl
• Vice-Chair of the Action
Dr. Minna Keinanen-Toivola
Satakunta Univ. App. Sciences, FI
minna.keinanen-toivola@samk.fi
3. Anti-MIcrobial Coating Innovations to prevent
infectious diseases (AMiCI)
2016-2020
Objectives
• To evaluate the impact of (introducing) AntiMicrobial
Coatings in healthcare on the spread of infections and on
the efficacy in fighting HealthCare Associated Infections
(HAI) and bacterial resistance to current antibiotics.
• To stimulate collaboration between industry and research
institutes using available knowledge, and disclose state of-
the- art nanotechnology and biotechnology knowledge, to
industrial partners.
• To develop, structure, coordinate and maintain a long-
term, flexible and open European network in the field of
AMC in healthcare.
4. AMiCI
Investigate new methods of
effective cleaning, additional
to the use of AMCs to ensure a
safe and more hygienic future
AMiCI Action Strategy
Focus on (eco)toxicological
risks and possible introduction
of AMR resulting from the use
of AMC
Development of lab and field
benchmark tests to evaluate
efficacy and efficiency of
AMCs to reduce bacterial
contamination in the
environment of
patients in healthcare
Reaching a conceptual
understanding of the
mechanisms and construction
of an active and sustainable
coating, to adapt current
and develop new
coatings to meet
ECHA standards
WG1
AM Materials
Safe-by-Design
WG2
Performance
Assessment
(lab-field-
benchmark)
WG4
The New
Cleaning
WG3
Adverse
Effects/ Risk
Benefit
Analysis
5. WG1 – Antimicrobial Coatings – Safe by Design
Dr. Hülya Olmez TUBITAK MRC Food Institute, Turkey WG Leader
Dr. Nuno Azevedo University of Porto, Portugal WG Vice Leader
WG2 – Performance Assessment of Antimicrobial Coatings
Pete Askew IMSL, United Kingdom WG Leader
Dr. Birgit Teunissen Zuyd University of Applied Sciences, The Netherlands WG Vice Leader
WG3 - Adverse Effects of Antimicrobial Coatings
Dr. Anne Kahru Institute of Chemical Physics and Biophysics, Estonia WG Leader
Dr. Merja Ahonen Satakunta University of Applied Sciences, Finland WG Vice Leader
WG4 – The new cleaning
Dr. Martina Modic Jozef Stefan Institute, Slovenia WG Leader
Prof. Dr. Colum Dunne University of Limerick, Ireland WG Vice Leader
WG5 – Communication and dissemination
Kazimierz Murzyn LifeScience Krakow Klaster, Poland WG Leader
Dr. Theofilos Papadopoulos Aristoteles University of Thessaloniki, Greece WG Vice Leader
6. Status of the Action
Parties
Country Date Country Date Country Date Country Date
Austria 28/08/2017
Belgium 21/12/2015 Bulgaria 05/01/2016 Croatia 20/04/2016 Czech
Republic
13/09/2016
Denmark 07/01/2016 Estonia 18/11/2015 Finland 24/11/2015 France 06/01/2016
Germany 24/11/2015 Greece 04/12/2015 Ireland 21/12/2015 Israel 09/12/2015
Italy 26/01/2016 Latvia 28/04/2016 Lithuania 05/01/2016 Malta 28/11/2015
Netherlands 26/11/2015 Norway 12/09/2016 Poland 12/02/2016 Portugal 22/01/2016
Romania 10/12/2015 Serbia 04/01/2016 Slovenia 11/01/2016 Spain 13/01/2016
Sweden 06/10/2016 Switzerland 21/01/2016 Turkey 20/02/2016 United
Kingdom
17/11/2015
fYR
Macedonia
22/12/2015 Montenegro 19/01/2018
Total: 31
COST International Partner Country: 1
Center for Biofilm Engineering – United States of America
9. Goal, setup & outcome
• MC & CG meeting: organizational and strategic
• Presentations of 4 WG topics (recordings see :
http://amici.lifescienceopenspace.pl/first-amici-working-group-
meetings-in-heerlen-a-great-success/ )
• World café: discussion on WG topics in multidisciplinary groups
• Publications:
10. Publications from Heerlen World cafe:
• WG1: Surface modifications for antimicrobial effects in the healthcare
setting: a critical overview; Adlhart C. et al. accepted Journal of Hospital
Infection (2018)
• WG2: in preparation
• WG3: Proactive Approach for Safe Use of Antimicrobial Coatings in
Healthcare Settings: Opinion of the COST Action Network AMiCI; Ahonen
M, Kahru A et al. International journal of environmental research and
public health (2017)
• WG4: Antimicrobial coatings for reduction of hospital acquired infection
and associated specialised cleaning: Opinion of the COST Action Network
AMiCI (CA15114); Dunne C. et al. submitted to the Journal of Hospital
Infection
11.
12. “Antimicrobial Coatings in Health Care:
from Innovations to the Market”
• Day 1: keynote speakers
• Day 2: management committee meeting, WG meetings
• Over 60 participants, 21 countries (researchers, companies, less
regulators)
-> For a coating to enter market registration can be the bottle neck
-> Need for wide risk-benefit analysis (WG3)
-> Need to benchmark cleaning procedures
http://www.samk.fi/en/uutiset/the-international-amici-conference-
hosted-by-samk-was-a-success/
• Day1: https://www.youtube.com/watch?v=Fl27Ojptg8U
• Day 2: https://www.youtube.com/watch?v=xIZIgu5OOQk
14. • National Institute of Chemical Physics and Biophysics,
Tallinn, Estonia
• Topic: development and spreading microbial
antibiotic resistance
• Audience: 25 AMICI members + dozen Estonian
researchers and students took part
• Lecturers:
• Prof. T. Tenson, Prof. I. Lutsar, Dr. P. Märtin, Dr. S.
Kõljalg*, dr T. Papadopolous*, Dr. O.M. Pereira, Dr.
M. Riool*)
*AMICI members
• The slides of the talks are on AMICI website
• The information on the successful Meeting was
published on Estonian Research Agency Website (in
Estonian) and on AMICI website (in English).
15. Day 2 afternoon
Roundtable & interactive discussion
• Conclusions
• No common global rules or acceptance schemes for AMCs are available.
Generally accepted global rules are needed to enable customers/ buyers/
end-users to evaluate the efficacy, safety and cost-benefits of various
products using AMC, and to minimize the risks of AMR development during
usage and disposal of the products.
• efficacy? one test method for all materials, clinical real-life studies are needed
• safety?
• environmental aspects?
• Biocide regulation as a partial answer to the need above?
• The “rules” in food & textile industry could be adopted with suitable parts to
AMCs used in inanimate surfaces of healthcare settings
16. STSMs
• 4 in GP1
• 6 in GP2:
• WG1: Evaluating the anti-biofilm activity of surfaces composed of ZnO/Ag
heterostructures (completed in Porto)
• WG1: Fabrication of electrospun antimicrobial nanofibers based on
phytochemicals (to be performed in Zurich)
• WG2: Antibacterial coatings on dental surfaces/implants (to be performed in
Italy)
• WG2: Development of lab based simulation tests (to be performed in Geleen)
• WG3: Development of an inventory on dissolution-driven environmental
effects of AMC-related nanoparticles (to be performed in Tallinn)
• WG4: Standard operating procedures in cleaning (?)
17. What did we learn?
• Many research laboratories are developing coatings to be used in
healthcare settings
• Not that many coatings available for hard surfaces in healthcare
• Few pilot studies with AMCs in patient rooms
19. Further issues
• ECI’s
• ITC conference grants
• News from AMiCI members, announcements, publications
AMiCI website www.amici-consortium.eu
contact person: Kazimierz Murzyn (kmurzyn@lifescience.pl)
• Grant opportunities
• Other issues?
• How did you experience virtual meeting?